BioSpace News Archive

As the 118th Congress kicks into gear, biopharma industry observers speculate that 2023 may be a challenging year.

The FDA asked Taysha Gene Therapies to dose more patients in a double-blinded, placebo-controlled trial before submitting a BLA for its giant axonal neuropathy candidate.

The partners will combine Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system, which is designed to provide individualized therapies to patients.

Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.

GSK has dropped two assets, an investigational celiac disease therapeutic and a Staphylococcus aureus vaccine hopeful, from its pipeline.

Orbit Discovery Limited announced it has entered into a multi target Research Agreement with Endevica Bio Inc., a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials.

IDEAYA Biosciences, Inc. announced its participation in the 2023 Guggenheim Oncology Conference.

BioCardia, Inc. today announce an amendment to their Clinical Research Supply and Support Agreement.

Leading health insurer and health care services company, Humana Inc . (NYSE: HUM) has hired health care industry veteran Sanjay Shetty, M.D., MBA, to lead its health care services business, CenterWell.

GreenLight Biosciences today announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.